CAPR (Capricor Therapeutics) Cyclically Adjusted Book per Share: $1.24 (As of Mar. 2026)


CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $26.41
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Cyclically Adjusted Book per Share?

Capricor Therapeutics CAPR -13.03% 37 Cyclically Adjusted Book per Share is $1.24 as of Mar. 2026. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Capricor Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $4.833. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.24 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Capricor Therapeutics's average Cyclically Adjusted Book Growth Rate was 31.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Capricor Therapeutics was 12.30% per year. The lowest was -58.90% per year. And the median was -2.80% per year.

As of today (2026-06-27), Capricor Therapeutics's current stock price is $26.41. Capricor Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $1.24. Capricor Therapeutics's Cyclically Adjusted PB Ratio of today is 21.30.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Capricor Therapeutics was 37.92. The lowest was 0.10. And the median was 1.20.


Capricor Therapeutics  (NAS:CAPR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Capricor Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=26.41/1.24
=21.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Capricor Therapeutics was 37.92. The lowest was 0.10. And the median was 1.20.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Capricor Therapeutics Cyclically Adjusted Book per Share Related Terms


Capricor Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Cyclically Adjusted Book per Share Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 -0.90 0.42 1.01 1.08

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.92 0.93 1.08 1.24

CAPR vs SNDX, SLS, AGIO: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted PB Ratio falls into.


CAPR
37GF Score
Capricor Therapeutics Inc CAPR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Capricor Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.833/330.2130*330.2130
=4.833

Current CPI (Mar. 2026) = 330.2130.

Capricor Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -2.850 241.018 -3.905
201609 0.023 241.428 0.031
201612 -1.871 241.432 -2.559
201703 -3.361 243.801 -4.552
201706 -2.914 244.955 -3.928
201709 -1.702 246.819 -2.277
201712 4.274 246.524 5.725
201803 3.766 249.554 4.983
201806 3.211 251.989 4.208
201809 2.270 252.439 2.969
201812 1.471 251.233 1.933
201903 1.111 254.202 1.443
201906 0.682 256.143 0.879
201909 0.855 256.759 1.100
201912 1.308 256.974 1.681
202003 1.044 258.115 1.336
202006 1.607 257.797 2.058
202009 1.504 260.280 1.908
202012 1.370 260.474 1.737
202103 1.596 264.877 1.990
202106 1.451 271.696 1.764
202109 1.521 274.310 1.831
202112 1.297 278.802 1.536
202203 1.013 287.504 1.163
202206 0.770 296.311 0.858
202209 0.624 296.808 0.694
202212 0.467 296.797 0.520
202303 0.246 301.836 0.269
202306 0.106 305.109 0.115
202309 -0.069 307.789 -0.074
202312 0.726 306.746 0.782
202403 0.583 312.332 0.616
202406 0.360 314.175 0.378
202409 1.693 315.301 1.773
202412 3.191 315.605 3.339
202503 2.795 319.799 2.886
202506 2.296 322.561 2.350
202509 1.834 324.800 1.865
202512 5.330 324.054 5.431
202603 4.833 330.213 4.833

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.24 mean?
Capricor Therapeutics (CAPR) has a Cyclically Adjusted Book per Share of $1.24 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Cyclically Adjusted Book per Share too high?
Capricor Therapeutics' current Cyclically Adjusted Book per Share is $1.24. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Cyclically Adjusted Book per Share compare to SNDX and SLS?
Capricor Therapeutics' Cyclically Adjusted Book per Share of $1.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Cyclically Adjusted Book per Share is $1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $26.41 — trading 442.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.24. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Cyclically Adjusted Book per Share is $1.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $26.41 is trading 442.3% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • Cyclically Adjusted Book per Share: $1.24
  • GF Value™: $4.87 vs. price of $26.41 (442.3% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.41
Price
$4.87
GF Value